Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T15556
|
||||
Former ID |
TTDR00556
|
||||
Target Name |
Plasminogen activator inhibitor-1
|
||||
Gene Name |
SERPINE1
|
||||
Synonyms |
Endothelial plasminogen activator inhibitor; PAI; PAI-1; Plasminogen activator inhibitor type 1; SERPINE1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Asthma [ICD10: J45] | ||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Thrombolysis [ICD9: 410, 415.1, 434.91, 459.9; ICD10: I21-I22, I26, I61-I63, I99.9] | |||||
Function |
Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.
|
||||
BioChemical Class |
Serpin family
|
||||
Target Validation |
T15556
|
||||
UniProt ID | |||||
Sequence |
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | HIF-1 signaling pathway | ||||
p53 signaling pathway | |||||
Hippo signaling pathway | |||||
Complement and coagulation cascades | |||||
Chagas disease (American trypanosomiasis) | |||||
NetPath Pathway | TWEAK Signaling Pathway | ||||
IL2 Signaling Pathway | |||||
TGF_beta_Receptor Signaling Pathway | |||||
PANTHER Pathway | Blood coagulation | ||||
Plasminogen activating cascade | |||||
p53 pathway | |||||
CCKR signaling map ST | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
p73 transcription factor network | |||||
E2F transcription factor network | |||||
HIF-2-alpha transcription factor network | |||||
Direct p53 effectors | |||||
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
HIF-1-alpha transcription factor network | |||||
Reactome | Platelet degranulation | ||||
CLOCK,NPAS2 activates circadian gene expression | |||||
SMAD4 heterotrimer regulates transcription | |||||
ECM proteoglycans | |||||
Dissolution of Fibrin Clot | |||||
WikiPathways | Senescence and Autophagy in Cancer | ||||
TGF Beta Signaling Pathway | |||||
Complement and Coagulation Cascades | |||||
SMAD4 heterotrimer | |||||
Blood Clotting Cascade | |||||
Extracellular matrix organization | |||||
Oncostatin M Signaling Pathway | |||||
Adipogenesis | |||||
Dissolution of Fibrin Clot | |||||
Circadian Clock | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 525337 | ClinicalTrials.gov (NCT02572336) A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA. | ||||
Ref 525438 | J Nat Prod. 1999 Feb;62(2):324-6.Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. | ||||
Ref 527117 | J Med Chem. 2004 Jul 1;47(14):3491-4.Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. | ||||
Ref 527611 | Bioorg Med Chem Lett. 2005 Aug 1;15(15):3514-8.Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1. | ||||
Ref 530810 | Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.